ALEC Stock Price, Alector Inc Quote, Chart

Market Summary

USD5.40+0.15

Market Closed

2.86%

ALEC Alerts

Losses in recent quarter

ALEC Stock Price

View Fullscreen

ALEC RSI Chart

ALEC Valuation

Market Cap

520.5M

Price/Earnings (Trailing)

-4.32

Price/Sales (Trailing)

5.4

Price/Free Cashflow

-2.62

ALEC Price/Sales (Trailing)

ALEC Profitability

Return on Equity

-67.42%

Return on Assets

-18.98%

Free Cashflow Yield

-38.21%

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

96.4M

Rev. Growth (Yr)

-3.96%

Rev. Growth (Qtr)

4.63%

ALEC Earnings

Earnings (TTM)

-120.6M

Earnings Growth (Yr)

21.32%

Earnings Growth (Qtr)

12.92%

Breaking Down ALEC Revenue

Last 7 days

1.5%

Last 30 days

-10.3%

Last 90 days

-10.6%

Trailing 12 Months

-26.5%

How does ALEC drawdown profile look like?

ALEC Financial Health

Current Ratio

3.53

ALEC Investor Care

Shares Dilution (1Y)

15.64%

Diluted EPS (TTM)

-1.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	96.4M	0	0	0
2023	125.7M	102.1M	96.3M	97.1M
2022	227.4M	300.7M	133.2M	133.6M
2021	18.0M	21.4M	197.9M	207.1M
2020	22.8M	19.0M	22.2M	21.1M
2019	28.4M	28.2M	24.4M	21.2M
2018	8.4M	15.2M	21.6M	27.7M
2017	1.2M	2.1M	2.9M	3.7M
2016	0	0	0	416.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alector Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	polaris venture management co. vi, l.l.c.	sold	-	-	-500,000	-
Apr 30, 2024	polaris venture management co. vi, l.l.c.	sold	-	-	-98,533	-
Apr 30, 2024	polaris venture management co. vi, l.l.c.	acquired	-	-	98,533	-
Mar 19, 2024	altmeyer mark	acquired	-	-	41,250	-
Mar 19, 2024	desouza errol b	acquired	-	-	41,250	-
Mar 04, 2024	grasso marc	sold	-39,561	6.9212	-5,716	chief financial officer
Mar 04, 2024	kenkare-mitra sara	sold	-70,386	6.9217	-10,169	president and head of r&d
Mar 04, 2024	romano gary	sold	-41,553	6.9245	-6,001	chief medical officer
Mar 04, 2024	rosenthal arnon	sold	-130,386	6.9218	-18,837	chief executive officer
Dec 05, 2023	garofalo elizabeth a.	gifted	-	-	-9,459	-

Which funds bought or sold ALEC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	PNC FINANCIAL SERVICES GROUP, INC.	sold off	-100	-48.00	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	289	7,514	11,383	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	7,754	7,754	-%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	unchanged	-	-48,082	147,683	0.02%
May 10, 2024	Campbell & CO Investment Adviser LLC	sold off	-100	-1,920,190	-	-%
May 10, 2024	VANGUARD GROUP INC	added	11.99	-5,430,880	29,573,700	-%
May 10, 2024	MACKENZIE FINANCIAL CORP	new	-	63,704	63,704	-%
May 10, 2024	BlackRock Inc.	added	5.14	-13,316,000	51,071,100	-%
May 10, 2024	JUPITER ASSET MANAGEMENT LTD	unchanged	-	-455,150	1,397,960	0.01%
May 10, 2024	MARK SHEPTOFF FINANCIAL PLANNING, LLC	unchanged	-	-588	1,806	-%

Are Funds Buying or Selling ALEC?

Are funds buying ALEC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALEC

No. of Funds

ALEC Alerts

Losses in recent quarter

Unveiling Alector Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.21%	4,386,541	SC 13G/A
Feb 12, 2024	morgan stanley	5.5%	4,605,044	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	polaris venture partners vi, l.p.	0.5%	498,468	SC 13G/A
Feb 08, 2024	rosenthal arnon	-	7,285,773	SC 13G
Jan 24, 2024	blackrock inc.	9.6%	8,068,553	SC 13G/A
Oct 13, 2023	fmr llc	-	0	SC 13G/A
Oct 10, 2023	fil ltd	-	0	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	4.9%	4,056,548	SC 13G/A
Feb 10, 2023	rosenthal arnon	-	6,884,362	SC 13G/A

Recent SEC filings of Alector Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading

Peers (Alternatives to Alector Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Alector Inc News

Latest updates

Alector Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.6%	16.00	15.00	9.00	56.00	17.00	14.00	15.00	80.00	24.00	14.00	182	7.00	4.00	5.00	6.00	3.00	7.00	6.00	3.00	7.00	6.00
Operating Expenses	-4.9%	60.00	63.00	60.00	60.00	67.00	70.00	63.00	70.00	69.00	70.00	56.00	62.00	57.00	58.00	60.00	50.00	49.00	38.00	37.00	34.00	26.00
S&GA Expenses	-100.0%	-	15.00	13.00	14.00	15.00	15.00	14.00	16.00	16.00	17.00	13.00	14.00	11.00	13.00	16.00	16.00	15.00	13.00	8.00	8.00	6.00
R&D Expenses	-5.4%	45.00	48.00	46.00	46.00	52.00	54.00	48.00	55.00	53.00	53.00	43.00	48.00	46.00	44.00	44.00	34.00	35.00	26.00	29.00	26.00	21.00
Income Taxes	-99.6%	0.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	12.9%	-36.08	-41.43	-44.47	1.00	-45.86	-52.43	-46.15	10.00	-44.62	-55.61	127	-55.15	-52.17	-52.18	-52.70	-45.33	-40.02	-30.53	-31.74	-24.56	-18.56
Net Income Margin	6.9%	-1.25*	-1.34*	-1.47*	-1.40*	-1.07*	-1.00*	-1.02*	0.12*	-0.13*	-0.18*	-0.17*	-9.90*	-	-	-	-	-	-	-	-	-
Free Cashflow	-33.6%	-61.88	-46.30	-46.45	-44.22	-49.57	-49.69	-50.97	-58.19	134	-49.82	444	-45.37	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.2%	635	622	672	709	748	788	837	890	954	815	854	397	440	488	532	572	619	422	450	477	496
Current Assets	2.8%	581	566	613	648	686	726	775	827	891	750	788	329	375	422	470	510	556	357	385	415	442
Cash Equivalents	-0.6%	74.00	75.00	102	132	196	154	184	172	455	331	517	126	111	51.00	85.00	93.00	161	91.00	87.00	69.00	61.00
Net PPE	-4.7%	21.00	22.00	23.00	24.00	25.00	26.00	26.00	26.00	26.00	27.00	28.00	29.00	29.00	30.00	31.00	32.00	33.00	34.00	34.00	32.00	22.00
Liabilities	-6.4%	457	488	510	512	565	573	584	601	687	514	518	213	213	221	221	217	227	227	231	232	230
Current Liabilities	-7.3%	165	178	155	132	99.00	94.00	161	149	143	140	133	74.00	64.00	68.00	71.00	66.00	72.00	62.00	59.00	67.00	56.00
Shareholder's Equity	33.4%	179	134	163	196	183	214	253	289	268	301	336	185	228	268	310	355	392	195	219	246	266
Retained Earnings	-5.1%	-746	-710	-668	-624	-625	-579	-527	-481	-490	-446	-390	-517	-462	-410	-357	-305	-259	-219	-189	-157	-132
Additional Paid-In Capital	9.6%	925	844	832	822	811	799	787	776	762	748	727	702	690	677	667	659	649	414	408	403	399
Shares Outstanding	13.6%	96.00	85.00	84.00	84.00	83.00	83.00	83.00	82.00	82.00	80.00	81.00	80.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	384	-	-	-	627	-	-	-	1,193	-	-	-	1,376	-	-	-	549	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-33.2%	-61,346	-46,070	-46,540	-43,004	-48,548	-48,925	-49,053	-57,442	135,091	-49,265	445,052	-44,543	-52,693	-47,658	-40,821	-45,942	-32,313	-28,827	-28,863	-18,052	-23,566
Share Based Compensation	-10.7%	10,307	11,542	10,059	10,222	10,975	10,963	10,766	12,478	11,939	12,706	10,201	9,078	8,800	8,902	8,030	6,948	6,642	5,238	4,104	3,694	3,245
Cashflow From Investing	-165.1%	-11,765	18,071	16,961	-21,815	88,701	18,381	60,530	-225,819	-12,106	-146,753	-69,054	56,591	109,553	11,552	33,013	-24,744	-124,872	30,057	45,909	26,422	-151,262
Cashflow From Financing	11952.2%	71,108	590	-	881	1,079	636	489	906	2,483	8,638	14,821	2,962	3,874	1,096	286	2,270	228,461	1,437	720	-116	170,312

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALEC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 15,893	$ 16,549
Operating expenses:
Research and development	45,167	51,887
General and administrative	14,434	14,777
Total operating expenses	59,601	66,664
Loss from operations	(43,708)	(50,115)
Other income, net	7,636	5,159
Loss before income taxes	(36,072)	(44,956)
Income tax expense	7	901
Net loss	(36,079)	(45,857)
Unrealized gain (loss) on marketable securities	(587)	2,376
Comprehensive loss	$ (36,666)	$ (43,481)
Net loss per share, basic	$ (0.38)	$ (0.55)
Net loss per share, diluted	$ (0.38)	$ (0.55)
Shares used in computing net loss per share, basic	93,810,177	83,102,296
Shares used in computing net loss per share, diluted	93,810,177	83,102,296

ALEC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 72,552	$ 74,555
Marketable securities	489,531	474,306
Prepaid expenses and other current assets	19,307	16,946
Total current assets	581,390	565,807
Property and equipment, net	20,835	21,861
Operating lease right-of-use assets	24,321	25,195
Restricted cash	1,546	1,546
Other assets	7,402	7,418
Total assets	635,494	621,827
Current liabilities:
Accounts payable	4,586	3,775
Accrued clinical supply costs	5,870	5,215
Accrued liabilities	19,385	30,378
Deferred revenue, current portion	73,352	82,975
Payable to collaboration partner	15,632	7,703
Refund liability to collaboration partner, current portion	37,557	39,440
Operating lease liabilities, current portion	8,535	8,462
Total current liabilities	164,917	177,948
Deferred revenue, long-term portion	204,575	210,845
Refund liability to collaboration partner, long-term portion	56,700	67,047
Operating lease liabilities, long-term portion	29,022	30,456
Other long-term liabilities	1,373	1,373
Total liabilities	456,587	487,669
Commitments and contingencies (Note 4)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 96,384,562 and 84,879,693 shares issued and outstanding as of March 31, 2024 and December 31, 2023	9	8
Additional paid-in capital	925,458	844,044
Accumulated other comprehensive income (loss)	(403)	184
Accumulated deficit	(746,157)	(710,078)
Total stockholders' equity	178,907	134,158
Total liabilities and stockholders’ equity	$ 635,494	$ 621,827

About Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Arnon Rosenthal Ph.D.
WEBSITE	alector.com
INDUSTRY	Biotechnology
EMPLOYEES	239

Alector Inc Frequently Asked Questions

What is the ticker symbol for Alector Inc? What does ALEC stand for in stocks?

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alector Inc (ALEC)?

As of Mon May 13 2024, market cap of Alector Inc is 520.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers. The fair value of Alector Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alector Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALEC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alector Inc a good stock to buy?

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

What is Alector Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ALEC's PE ratio (Price to Earnings) is -4.32 and Price to Sales (PS) ratio is 5.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.